Receptor de la tirosina quinasa

Explorar temas relacionados

First complete interactome map of human receptor tyrosine kinases and phosphatases

First complete interactome map of human receptor tyrosine kinases and phosphatases

Receptor Tyrosine Kinases : Structure, Functions and Role in Human Disease (Reprint) (Paperback)

Receptor Tyrosine Kinases : Structure, Functions and Role in Human Disease (Reprint) (Paperback)

Receptor Tyrosine Kinases Part 4 - YouTube

Receptor Tyrosine Kinases Part 4 - YouTube

Sunitinib (Sutent) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib was the first cancer drug simultaneously approved for two different indications. Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs).  These include all PDGF-Rs and VEGFRs, which play a role in both tumor angiogenesis and tumor cell proliferation.

Sunitinib (Sutent) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib was the first cancer drug simultaneously approved for two different indications. Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs). These include all PDGF-Rs and VEGFRs, which play a role in both tumor angiogenesis and tumor cell proliferation.

Access : Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas : Modern Pathology

Access : Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas : Modern Pathology

Receptor Tyrosine Kinases: Methods and Protocols

Receptor Tyrosine Kinases: Methods and Protocols (Paperback)

Receptor Tyrosine Kinases: Methods and Protocols

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK).

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK).

A schematic shows how the binding of a ligand to receptor tyrosine kinases (RTKs) results in the activation of the RTKs. The RTKs are in a horizontal plasma membrane. Four different stages are shown: the RTKs before ligand binding, the dimerization of the RTKs after ligand binding, the phosphorylation of the RTKs, and the binding of various cytoplasmic proteins to the RTKs.

A schematic shows how the binding of a ligand to receptor tyrosine kinases (RTKs) results in the activation of the RTKs. The RTKs are in a horizontal plasma membrane. Four different stages are shown: the RTKs before ligand binding, the dimerization of the RTKs after ligand binding, the phosphorylation of the RTKs, and the binding of various cytoplasmic proteins to the RTKs.

Quizartinib is an orally available small molecule with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis.

Quizartinib is an orally available small molecule with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis.

Pinterest
Buscar